← Leaderboards
J Michael Mathis
Louisiana State Univ Hsc Shreveport
$3,551,231
Attributed
$4,736,120
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $629.4K · FY2006–19$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$4,736,120 · 7
By mechanism
R01$3,514,655 · 3
R42$865,002 · 1
R21$256,463 · 2
R41$100,000 · 1
Top collaborators
- David T Curiel5 shared
Most similar at Louisiana State Univ Hsc Shreveport
Same institution · by research overlap
- Heather E Kleiner-Hancock$1,459,790
Others in their field
Top investigators on “Gene Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$164,199,916
- Gregory H Reaman · National Childhood Cancer Foundation$155,841,493
- Randall J Bateman · Washington University$122,781,098
- Eric Martin McDade · Washington University$94,632,845
- Ronald G Crystal · Weill Medical College Of Cornell Univ$82,649,124
- Robert B. Diasio · University Of Alabama At Birmingham$73,470,685
Research focus
Gene TherapyIn VivoBaseCellsGenesMalignant NeoplasmsTumorPre-ClinicalTherapeutic IndexTissuesModificationCellular TransductionNeoplasticNeoplastic CellGeneticAdenovirus VectorLiverBiodistributionDesignSerotypingAdenovirusesSpecificityClinical TrialsTechnology
Grant awards (17)
Astrocyte-TAAR1 & METH in HAND$346,750
R01 · FY2019 · DA · contact PI
Astrocyte-TAAR1 & METH in HAND$346,750
R01 · FY2018 · DA · contact PI
Targeted-and Image-Based Adenovirus Cancer Therapeutic Vectors$469,520
R01 · FY2015 · CA
Targeted-and Image-Based Adenovirus Cancer Therapeutic Vectors$460,508
R01 · FY2014 · CA
Targeted-and Image-Based Adenovirus Cancer Therapeutic Vectors$449,047
R01 · FY2013 · CA
Targeted-and Image-Based Adenovirus Cancer Therapeutic Vectors$472,780
R01 · FY2012 · CA
Targeting multiple skin cancer pathways using citrus auraptene and ATRA$156,600
R21 · FY2012 · CA · contact PI
Targeted-and Image-Based Adenovirus Cancer Therapeutic Vectors$517,924
R01 · FY2011 · CA
Cancer dual-targeting of an infectivity-enhance CRAd$412,501
R42 · FY2009 · CA · contact PI
Cancer dual-targeting of an infectivity-enhance CRAd$40,000
R42 · FY2009 · CA · contact PI
Cancer dual-targeting of an infectivity-enhance CRAd$412,501
R42 · FY2008 · CA · contact PI
Cancer dual-targeting of an infectivity-enchanced CRAd$100,000
R41 · FY2006 · CA · contact PI
ADENOVIRUS BASED P53 GENE THERAPY FOR OVARIAN CANCER$117,966
R01 · FY2003 · CA
ADENOVIRUS BASED P53 GENE THERAPY FOR OVARIAN CANCER$114,527
R01 · FY2002 · CA
ADENOVIRUS BASED P53 GENE THERAPY FOR OVARIAN CANCER$111,193
R01 · FY2001 · CA
ADENOVIRUS BASED P53 GENE THERAPY FOR OVARIAN CANCER$107,690
R01 · FY2000 · CA
ROLE OF CYSTATIN M IN BREAST TUMOR PROGRESSION$99,863
R21 · FY2000 · CA